Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo

Biomaterials

Volumn 120, Issue , 2017, Pages 126-138

  Mohamed Suffian, Izzat Fahimuddin Bin ^a   Wang, Julie Tzu Wen ^a   Hodgins, Naomi O ^a   Klippstein, Rebecca ^a   Garcia Maya, Mitla ^a   Brown, Paul ^a   Nishimura, Yuya ^b   Heidari, Hamed ^c   Bals, Sara ^c   Sosabowski, Jane K ^d   Ogino, Chiaki ^b   Kondo, Akihiko ^b   Al Jamal, Khuloud T ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KOBE UNIVERSITY   (Japan)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Active targeting; Affibody; Hepatitis B virus core particles; Human epidermal growth factor receptor 2; Virus like particles

Indexed keywords

AMINO ACIDS; BINS; CELLS; DISEASES; NANOPARTICLES; ONCOLOGY; PROTEINS; TUMORS;

ACTIVE TARGETING; AFFIBODY; CORE PARTICLES; HUMAN EPIDERMAL GROWTH FACTOR; VIRUS-LIKE PARTICLES;

VIRUSES;

ARGININE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEPATITIS B VIRUS CORE PARTICLE; NANOCARRIER; TECHNETIUM 99M; UNCLASSIFIED DRUG; CORE PROTEIN; ERBB2 PROTEIN, HUMAN; NANOCAPSULE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC FORCE MICROSCOPY; CANCER CELL; CANCER DIAGNOSIS; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; CT-SPECT SCANNER; DRUG DELIVERY SYSTEM; DRUG TARGETING; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION SYSTEM; GENETIC ENGINEERING; HEPATITIS B; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MELANOMA; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ANIMAL; CHEMISTRY; EXPERIMENTAL NEOPLASM; GENETICS; METABOLISM; PROCEDURES; PROTEIN ENGINEERING; TUMOR CELL LINE; VIRION;

ANIMALS; CELL LINE, TUMOR; HUMANS; MALE; MICE; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; PROTEIN ENGINEERING; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; VIRAL CORE PROTEINS; VIRION;

EID: 85007545211     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.12.012     Document Type: Article

References (78)

1. [1] Schneble, E.J., Graham, L.J., Shupe, M.P., Flynt, F.L., Banks, K.P., Kirkpatrick, A.D., Nissan, A., Henry, L., Stojadinovic, A., Shumway, N.M., Avital, I., Peoples, G.E., Setlik, R.F., Current approaches and challenges in early detection of breast cancer recurrence. J. Cancer 5:4 (2014), 281–290.
2. [2] Tiwari, G., Tiwari, R., Sriwastawa, B., Bhati, L., Pandey, S., Pandey, P., Bannerjee, S.K., Drug delivery systems: an updated review. Int. J. Pharm. Investig. 2:1 (2012), 2–11.
3. [3] Singh, P., Prasuhn, D., Yeh, R.M., Destito, G., Rae, C.S., Osborn, K., Finn, M.G., Manchester, M., Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J. Control Release 120:1–2 (2007), 41–50.
4. [4] Kaczmarczyk, S.J., Sitaraman, K., Young, H.A., Hughes, S.H., Chatterjee, D.K., Protein delivery using engineered virus-like particles. Proc. Natl. Acad. Sci. U. S. A. 108:41 (2011), 16998–17003.
5. [5] Brune, K.D., Leneghan, D.B., Brian, I.J., Ishizuka, A.S., Bachmann, M.F., Draper, S.J., Biswas, S., Howarth, M., Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization. Sci. Rep., 6, 2016, 19234.
6. [6] Pumpens, P., Grens, E., The true story and advantages of the famous Hepatitis B virus core particles: outlook 2016. Mol. Biol. 50:4 (2016), 489–509.
7. [7] Cooper, A., Shaul, Y., Recombinant viral capsids as an efficient vehicle of oligonucleotide delivery into cells. Biochem. Biophys. Res. Commun. 327:4 (2005), 1094–1099.
8. [8] Lewellyn, E.B., Loeb, D.D., The arginine clusters of the carboxy-terminal domain of the core protein of hepatitis B virus make pleiotropic contributions to genome replication. J. Virol. 85:3 (2011), 1298–1309.
9. [9] Zlotnick, A., Johnson, J.M., Wingfield, P.W., Stahl, S.J., Endres, D., A theoretical model successfully identifies features of hepatitis B virus capsid assembly. Biochemistry 38:44 (1999), 14644–14652.
10. [10] Cooper, A., Shaul, Y., Clathrin-mediated endocytosis and lysosomal cleavage of hepatitis B virus capsid-like core particles. J. Biol. Chem. 281:24 (2006), 16563–16569.
11. [11] Borisova, G., Arya, B., Dislers, A., Borschukova, O., Tsibinogin, V., Skrastina, D., Eldarov, M.A., Pumpens, P., Skryabin, K.G., Grens, E., Hybrid hepatitis B virus nucleocapsid bearing an immunodominant region from hepatitis B virus surface antigen. J. Virol. 67:6 (1993), 3696–3701.
12. [12] Karpenko, L.I., Ivanisenko, V.A., Pika, I.A., Chikaev, N.A., Eroshkin, A.M., Veremeiko, T.A., Ilyichev, A.A., Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble. Amino Acids 18:4 (2000), 329–337.
13. [13] Kratz, P.A., Böttcher, B., Nassal, M., Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Natl. Acad. Sci. U. S. A. 96:5 (1999), 1915–1920.
14. [14] Schodel, F., Wirtz, R., Peterson, D., Hughes, J., Warren, R., Sadoff, J., Milich, D., Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J. Exp. Med. 180:3 (1994), 1037–1046.
15. [15] Nygren, P.A., Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 275:11 (2008), 2668–2676.
16. [16] Eigenbrot, C., Ultsch, M., Dubnovitsky, A., Abrahmsen, L., Hard, T., Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc. Natl. Acad. Sci. U. S. A. 107:34 (2010), 15039–15044.
17. [17] Badar, A., Williams, J., de Rosales, R.T.M., Tavaré, R., Kampmeier, F., Blower, P.J., Mullen, G.E.D., Optimising the radiolabelling properties of technetium tricarbonyl and His-tagged proteins. EJNMMI Res., 4, 2014 14–14.
18. [18] Kuntsche, J., Horst, J.C., Bunjes, H., Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems. Int. J. Pharm. 417:1–2 (2011), 120–137.
19. [19] Jiang, W., Chiu, W., Cryoelectron microscopy of icosahedral virus particles. Methods Mol. Biol. Clift. N.J. 369 (2007), 345–363.
20. [20] Yu, X., Jin, L., Jih, J., Shih, C., Zhou, Z.H., 3.5A cryoEM structure of hepatitis B virus core assembled from full-length core protein. PLoS One, 8(9), 2013, e69729.
21. [21] Wilkie, S., van Schalkwyk, M.C., Hobbs, S., Davies, D.M., van der Stegen, S.J., Pereira, A.C., Burbridge, S.E., Box, C., Eccles, S.A., Maher, J., Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 32:5 (2012), 1059–1070.
22. [22] Nishimura, Y., Mimura, W., Mohamed Suffian, I.F., Amino, T., Ishii, J., Ogino, C., Kondo, A., Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule. J. Biochem. 153:3 (2013), 251–256.
23. [23] Glasel, J.A., Validity of nucleic acid purities monitored by 260nm/280nm absorbance ratios. BioTechniques 18:1 (1995), 62–63.
24. [24] Ramqvist, T., Andreasson, K., Dalianis, T., Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin. Biol. Ther. 7:7 (2007), 997–1007.
25. [25] Pumpens, P., Borisova, G.P., Crowther, R.A., Grens, E., Hepatitis B virus core particles as epitope carriers. Intervirology 38:1–2 (1995), 63–74.
26. [26] Sominskaya, I., Skrastina, D., Dislers, A., Vasiljev, D., Mihailova, M., Ose, V., Dreilina, D., Pumpens, P., Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes. Clin. Vaccine Immunol. CVI 17:6 (2010), 1027–1033.
27. [27] Burrell, C.J., Mackay, P., Greenaway, P.J., Hofschneider, P.H., Murray, K., Expression in Escherichia coli of hepatitis B virus DNA sequences cloned in plasmid pBR322. Nature 279:5708 (1979), 43–47.
28. [28] Pasek, M., Goto, T., Gilbert, W., Zink, B., Schaller, H., MacKay, P., Leadbetter, G., Murray, K., Hepatitis B virus genes and their expression in E. coli. Nature 282:5739 (1979), 575–579.
29. [29] Edman, J.C., Hallewell, R.A., Valenzuela, P., Goodman, H.M., Rutter, W.J., Synthesis of hepatitis B surface and core antigens in E. coli. Nature 291:5815 (1981), 503–506.
30. [30] Birnbaum, F., Nassal, M., Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. J. Virol. 64:7 (1990), 3319–3330.
31. [31] Salfeld, J., Pfaff, E., Noah, M., Schaller, H., Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J. Virol. 63:2 (1989), 798–808.
32. [32] Pumpens, P., Grens, E., HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44:2–3 (2001), 98–114.
33. [33] Crowther, R.A., Kiselev, N.A., Bottcher, B., Berriman, J.A., Borisova, G.P., Ose, V., Pumpens, P., Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy. Cell 77:6 (1994), 943–950.
34. [34] Weigand, K., Knaust, A., Schaller, H., Assembly and export determine the intracellular distribution of hepatitis B virus core protein subunits. J. Gen. Virol. 91:Pt 1 (2010), 59–67.
35. [35] Rusnati, M., Tulipano, G., Urbinati, C., Tanghetti, E., Giuliani, R., Giacca, M., Ciomei, M., Corallini, A., Presta, M., The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists. J. Biol. Chem. 273:26 (1998), 16027–16037.
36. [36] Console, S., Marty, C., Garcia-Echeverria, C., Schwendener, R., Ballmer-Hofer, K., Antennapedia and HIV transactivator of transcription (TAT) “protein transduction domains” promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J. Biol. Chem. 278:37 (2003), 35109–35114.
37. [37] Bin Mohamed Suffian, I.F., Nishimura, Y., Morita, K., Nakamura-Tsuruta, S., Al-Jamal, K.T., Ishii, J., Ogino, C., Kondo, A., Mutation of arginine residues to avoid non-specific cellular uptakes for hepatitis B virus core particles. J. Nanobiotechnol., 13, 2015, 15.
38. [38] Nassal, M., The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsulation and productive viral positive-strand DNA synthesis but not for virus assembly. J. Virol. 66:7 (1992), 4107–4116.
39. [39] S.A. Wynne, R.A. Crowther, A.G.W. Leslie, The crystal structure of the human hepatitis B virus capsid, Mol. Cell 3(6) 771–780.
40. [40] Roseman, A.M., Borschukova, O., Berriman, J.A., Wynne, S.A., Pumpens, P., Crowther, R.A., Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies. J. Mol. Biol. 423:1 (2012), 63–78.
41. [41] Abbing, A., Blaschke, U.K., Grein, S., Kretschmar, M., Stark, C.M., Thies, M.J., Walter, J., Weigand, M., Woith, D.C., Hess, J., Reiser, C.O., Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J. Biol. Chem. 279:26 (2004), 27410–27421.
42. [42] Brown, W.L., Mastico, R.A., Wu, M., Heal, K.G., Adams, C.J., Murray, J.B., Simpson, J.C., Lord, J.M., Taylor-Robinson, A.W., Stockley, P.G., RNA bacteriophage capsid-mediated drug delivery and epitope presentation. Intervirology 45:4–6 (2002), 371–380.
43. [43] Chatterji, A., Ochoa, W., Shamieh, L., Salakian, S.P., Wong, S.M., Clinton, G., Ghosh, P., Lin, T., Johnson, J.E., Chemical conjugation of heterologous proteins on the surface of Cowpea mosaic virus. Bioconj. Chem. 15:4 (2004), 807–813.
44. [44] Lua, L.H.L., Connors, N.K., Sainsbury, F., Chuan, Y.P., Wibowo, N., Middelberg, A.P.J., Bioengineering virus-like particles as vaccines. Biotechnol. Bioeng. 111:3 (2014), 425–440.
45. [45] Pushko, P., Pumpens, P., Grens, E., Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology 56:3 (2013), 141–165.
46. [46] Liu, J., Dai, S., Wang, M., Hu, Z., Wang, H., Deng, F., Virus like particle-based vaccines against emerging infectious disease viruses. Virol. Sin. 31:4 (2016), 279–287.
47. [47] Almeida, J.P., Chen, A.L., Foster, A., Drezek, R., In vivo biodistribution of nanoparticles. Nanomed. Lond. Engl. 6:5 (2011), 815–835.
48. [48] Ernsting, M.J., Murakami, M., Roy, A., Li, S.D., Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J. Control Release 172:3 (2013), 782–794.
49. [49] Fantozzi, A., Christofori, G., Mouse models of breast cancer metastasis. Breast Cancer Res. 8:4 (2006), 1–11.
50. [50] Khanna, C., Hunter, K., Modeling metastasis in vivo. Carcinogenesis 26:3 (2005), 513–523.
51. [51] House, C., Hernandez, L., Annunziata, C., Recent technological advances in using mouse models to study ovarian cancer. Front. Oncol., 4(26), 2014.
52. [52] Vassileva, V., Moriyama, E.H., De Souza, R., Grant, J., Allen, C.J., Wilson, B.C., Piquette-Miller, M., Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging. Br. J. Cancer 99:12 (2008), 2037–2043.
53. [53] Badar, A., Williams, J., de Rosales, R.T., Tavare, R., Kampmeier, F., Blower, P.J., Mullen, G.E., Optimising the radiolabelling properties of technetium tricarbonyl and His-tagged proteins. EJNMMI Res., 4(1), 2014, 14.
54. [54] Waibel, R., Alberto, R., Willuda, J., Finnern, R., Schibli, R., Stichelberger, A., Egli, A., Abram, U., Mach, J.P., Pluckthun, A., Schubiger, P.A., Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat. Biotechnol. 17:9 (1999), 897–901.
55. [55] Wizemann, H., von Brunn, A., Purification of E. coli-expressed HIS-tagged hepatitis B core antigen by Ni2+ -chelate affinity chromatography. J. Virol. Methods 77:2 (1999), 189–197.
56. [56] Tait, J.F., Smith, C., Gibson, D.F., Development of annexin V mutants suitable for labeling with Tc(i)-carbonyl complex. Bioconj. Chem. 13:5 (2002), 1119–1123.
57. [57] Vishnu Vardhan, G.P., Savithri, H.S., Murthy, M.R.N., Hema, M., Biodistribution and toxicity evaluation of sesbania mosaic virus nanoparticles in mice. Arch. Virol. 161:10 (2016), 2673–2681.
58. [58] Kaiser, C.R., Flenniken, M.L., Gillitzer, E., Harmsen, A.L., Harmsen, A.G., Jutila, M.A., Douglas, T., Young, M.J., Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo. Int. J. Nanomed. 2:4 (2007), 715–733.
59. [59] Aanei, I.L., ElSohly, A.M., Farkas, M.E., Netirojjanakul, C., Regan, M., Murphy, S.T., O'Neil, J.P., Seo, Y., Francis, M.B., Biodistribution of antibody-MS2 viral capsid conjugates in breast cancer models. Mol. Pharm. 13:11 (2016), 3764–3772.
60. [60] Fisher, K., Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Curr. Opin. Mol. Ther. 8:4 (2006), 301–313.
61. [61] Peiser, L., Mukhopadhyay, S., Gordon, S., Scavenger receptors in innate immunity. Curr. Opin. Immunol. 14:1 (2002), 123–128.
62. [62] Green, N.K., Herbert, C.W., Hale, S.J., Hale, A.B., Mautner, V., Harkins, R., Hermiston, T., Ulbrich, K., Fisher, K.D., Seymour, L.W., Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 11:16 (2004), 1256–1263.
63. [63] Jokerst, J.V., Lobovkina, T., Zare, R.N., Gambhir, S.S., Nanoparticle PEGylation for imaging and therapy. Nanomed. Lond. Engl. 6:4 (2011), 715–728.
64. [64] van Vlerken, L.E., Vyas, T.K., Amiji, M.M., Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 24:8 (2007), 1405–1414.
65. [65] Raja, K.S., Wang, Q., Gonzalez, M.J., Manchester, M., Johnson, J.E., Finn, M.G., Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules 4:3 (2003), 472–476.
66. [66] Chaudhary, K., Haddadin, S., Nistala, R., Papageorgio, C., Intraperitoneal drug therapy: an advantage. Curr. Clin. Pharmacol. 5:2 (2010), 82–88.
67. [67] Yang, S., Feng, R., Pan, Z.-C., Jiang, T., Xu, Q., Chen, Q., A comparison of intravenous plus intraperitoneal chemotherapy with intravenous chemotherapy alone for the treatment of gastric cancer: a meta-analysis. Sci. Rep., 5, 2015, 12538.
68. [68] Dedrick, R.L., Myers, C.E., Bungay, P.M., DeVita, V.T. Jr., Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62:1 (1978), 1–11.
69. [69] Deshane, J., Siegal, G.P., Wang, M., Wright, M., Bucy, R.P., Alvarez, R.D., Curiel, D.T., Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an Anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy. Gynecol. Oncol. 64:3 (1997), 378–385.
70. [70] Hwang, R.F., Gordon, E.M., Anderson, W.F., Parekh, D., Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery 124:2 (1998), 143–150 discussion 150–1.
71. [71] Landen, C.N., Merritt, W.M., Mangala, L.S., Sanguino, A.M., Bucana, C., Lu, C., Lin, Y.G., Han, L.Y., Kamat, A.A., Schmandt, R., Coleman, R.L., Gershenson, D.M., Lopez-Berestein, G., Sood, A.K., Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol. Ther. 5:12 (2006), 1708–1713.
72. [72] Jang, S.H., Wientjes, M.G., Lu, D., Au, J.L., Drug delivery and transport to solid tumors. Pharm. Res. 20:9 (2003), 1337–1350.
73. [73] Wang, J., Lu, Z., Gao, Y., Wientjes, M.G., Au, J.L.S., Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. Nanomedicine 6:9 (2011), 1605–1620.
74. [74] Paszek, M.J., Zahir, N., Johnson, K.R., Lakins, J.N., Rozenberg, G.I., Gefen, A., Reinhart-King, C.A., Margulies, S.S., Dembo, M., Boettiger, D., Hammer, D.A., Weaver, V.M., Tensional homeostasis and the malignant phenotype. Cancer Cell 8:3 (2005), 241–254.
75. [75] Netti, P.A., Berk, D.A., Swartz, M.A., Grodzinsky, A.J., Jain, R.K., Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60:9 (2000), 2497–2503.
76. [76] Minchinton, A.I., Tannock, I.F., Drug penetration in solid tumours. Nat. Rev. Cancer 6:8 (2006), 583–592.
77. [77] Holback, H., Yeo, Y., Intratumoral drug delivery with nanoparticulate carriers. Pharm. Res. 28:8 (2011), 1819–1830.
78. [78] Prasad, V.V.T.S., Gopalan, R.O.G., Continued use of MDA-MB-435, a melanoma cell line, as a model for human breast cancer, even in year, 2014. Npj Breast Cancer, 1, 2015, 15002.